Imaging β-amyloid using [18F]flutemetamol positron emission tomography: from dosimetry to clinical diagnosis

Heurling, Kerstin; Leuzy, Antoine; Zimmer, Eduardo R.; Lubberink, Mark; Nordberg, Agneta

doi:10.1007/s00259-015-3208-1

Cited by 38 publications

(19 citation statements)

References 86 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…flutemetamol (Nelissen et al, 2009). Although it is not a stilbene derivative, it is important to note that [ 18 F]flutemetamol has demonstrated dosimetry comparable with other 18 F-labelled radiopharmaceuticals (Heurling, Leuzy, Zimmer, Lubberink, & Nordberg, 2016). Additional commonalities shared by these two tracers with [ 18 F]florbetapir include high rates of sensitivity and specificity in diagnosing AD (Barthel et al, 2011;Hatashita et al, 2014;Rowe et al, 2008;Tiepolt et al, 2013;Vandenberghe et al, 2010;Villemagne et al, 2011) and…”

Section: F-labelled Amyloid Tracersmentioning

confidence: 99%

“…Moreover, a positive amyloid scan for MCI patients indicates a greater risk of disease progression to AD.While 18 F-labelled amyloid tracers are equivalent in their degree of diagnostic accuracy, [ 18 F]florbetapir shows particularly fast brain kinetics relative to others(Wong et al, 2010). Although it is not a stilbene derivative, it is important to note that [ 18 F]flutemetamol has demonstrated dosimetry comparable with other 18 F-labelled radiopharmaceuticals(Heurling, Leuzy, Zimmer, Lubberink, & Nordberg, 2016). Although it is not a stilbene derivative, it is important to note that [ 18 F]flutemetamol has demonstrated dosimetry comparable with other 18 F-labelled radiopharmaceuticals(Heurling, Leuzy, Zimmer, Lubberink, & Nordberg, 2016).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Applications of amyloid, tau, and neuroinflammation PET imaging to Alzheimer's disease and mild cognitive impairment

Chandra

Valkimadi

Pagano

et al. 2019

Human Brain Mapping

141

114

View full text Add to dashboard Cite

Alzheimer's disease (AD) is a devastating and progressive neurodegenerative disease for which there is no cure. Mild cognitive impairment (MCI) is considered a prodromal stage of the disease. Molecular imaging with positron emission tomography (PET) allows for the in vivo visualisation and tracking of pathophysiological changes in AD and MCI. PET is a very promising methodology for differential diagnosis and novel targets of PET imaging might also serve as biomarkers for disease‐modifying therapeutic interventions. This review provides an overview of the current status and applications of in vivo molecular imaging of AD pathology, specifically amyloid, tau, and microglial activation. PET imaging studies were included and evaluated as potential biomarkers and for monitoring disease progression. Although the majority of radiotracers showed the ability to discriminate AD and MCI patients from healthy controls, they had various limitations that prevent the recommendation of a single technique or tracer as an optimal biomarker. Newer research examining amyloid, tau, and microglial PET imaging in combination suggest an alternative approach in studying the disease process.

show abstract

Section: F-labelled Amyloid Tracersmentioning

confidence: 99%

mentioning

confidence: 99%

Applications of amyloid, tau, and neuroinflammation PET imaging to Alzheimer's disease and mild cognitive impairment

Chandra

Valkimadi

Pagano

et al. 2019

Human Brain Mapping

141

114

View full text Add to dashboard Cite

show abstract

“…However, these tissue alterations are common to many neurodegenerative disorders, and thus cannot be used to unequivocally distinguish AD from other types of dementia [96, 153]. Advanced positron emission tomography (PET) brain imaging of hallmark amyloid and tau AD pathology using various radioactive tracers (e.g., 11 C-Pittsburgh compound B, PiB [125], 18 F-florbetapir [45], 18 F-flutemetamol [80], 18 F-florbetaben [173], 18 F-TKH5105, and 18 F-T807 [89]) provides disease specificity and facilitates ongoing research. However, it may be difficult to deploy this technology for population-wide screening of preclinical signs due to high cost, necessity of using radioactive isotopes, limited resolution, and the resulting unfeasibility of longitudinal studies [144].…”

Section: Introductionmentioning

confidence: 99%

Ocular indicators of Alzheimer’s: exploring disease in the retina

et al. 2016

View full text Add to dashboard Cite

Although historically perceived as a disorder confined to the brain, our understanding of Alzheimer’s disease (AD) has expanded to include extra-cerebral manifestation, with mounting evidence of abnormalities in the eye. Among ocular tissues, the retina, a developmental outgrowth of the brain, is marked by an array of pathologies in patients suffering from AD, including nerve fiber layer thinning, degeneration of retinal ganglion cells, and changes to vascular parameters. While the hallmark pathological signs of AD, amyloid β-protein (Aβ) plaques and neurofibrillary tangles (NFT) comprising hyperphosphorylated tau (pTau) protein, have long been described in the brain, identification of these characteristic biomarkers in the retina has only recently been reported. In particular, Aβ deposits were discovered in post-mortem retinas of advanced and early stage cases of AD, in stark contrast to non-AD controls. Subsequent studies have reported elevated Aβ42/40 peptides, morphologically diverse Aβ plaques, and pTau in the retina. In line with the above findings, animal model studies have reported retinal Aβ deposits and tauopathy, often correlated with local inflammation, retinal ganglion cell degeneration, and functional deficits. This review highlights the converging evidence that AD manifests in the eye, especially in the retina, which can be imaged directly and non-invasively. Visual dysfunction in AD patients, traditionally attributed to well-documented cerebral pathology, can now be reexamined as a direct outcome of retinal abnormalities. As we continue to study the disease in the brain, the emerging field of ocular AD warrants further investigation of how the retina may faithfully reflect the neurological disease. Indeed, detection of retinal AD pathology, particularly the early presenting amyloid biomarkers, using advanced high-resolution imaging techniques may allow large-scale screening and monitoring of at-risk populations.

show abstract

“…There has been tremendous progress made towards achieving this goal. Ligands have been developed for visualizing amyloid or tau pathologies in the brain by positron emission tomography (PET) [6, 7]. The utility of amyloid imaging and cerebrospinal fluid (CSF) biomarkers of Aβ and tau for clinical diagnosis has been validated in large cohorts and population studies, as well as in neuropathologically confirmed cases [8–15].…”

Section: Introductionmentioning

confidence: 99%

Amyloid Beta and Tau as Alzheimer’s Disease Blood Biomarkers: Promise From New Technologies

2017

View full text Add to dashboard Cite

The utility of the levels of amyloid beta (Aβ) peptide and tau in blood for diagnosis, drug development, and assessment of clinical trials for Alzheimer’s disease (AD) has not been established. The lack of availability of ultra-sensitive assays is one critical issue that has impeded progress. The levels of Aβ species and tau in plasma and serum are much lower than levels in cerebrospinal fluid. Furthermore, plasma or serum contain high levels of assay-interfering factors, resulting in difficulties in the commonly used singulex or multiplex ELISA platforms. In this review, we focus on two modern immune-complex-based technologies that show promise to advance this field. These innovative technologies are immunomagnetic reduction technology and single molecule array technology. We describe the technologies and discuss the published studies using these technologies. Currently, the potential of utilizing these technologies to advance Aβ and tau as blood-based biomarkers for AD requires further validation using already collected large sets of samples, as well as new cohorts and population-based longitudinal studies.

show abstract

Imaging β-amyloid using [18F]flutemetamol positron emission tomography: from dosimetry to clinical diagnosis

Cited by 38 publications

References 86 publications

Applications of amyloid, tau, and neuroinflammation PET imaging to Alzheimer's disease and mild cognitive impairment

Applications of amyloid, tau, and neuroinflammation PET imaging to Alzheimer's disease and mild cognitive impairment

Ocular indicators of Alzheimer’s: exploring disease in the retina

Amyloid Beta and Tau as Alzheimer’s Disease Blood Biomarkers: Promise From New Technologies

Contact Info

Product

Resources

About